News

Biotechnology

BridgeBio Pharma Inks Licensing Deal With Bristol Myers Squibb Worth up to $905 Million

Edward Kim | Equities.com |

BMY will pay BBIO $90 million in upfront cash.


PepGen Goes Public in $108 Million IPO

Edward Kim | Equities.com |

The company is developing treatments for serious genetic diseases, with an initial focus on neuromuscular diseases.


Aeglea BioTherapeutics Raises $45 Million Via Registered Direct Offering

Edward Kim | Equities.com |

The company is waiting on FDA review of its lead product candidate.


Biogen CEO Michel Vounatsos To Step Down After Commercial Failure of Alzheimer's Drug

Edward Kim | Equities.com |

Biogen will also halt marketing of Aduhelm.


Five Fallen Biotech Stocks We're Watching for Rebounds

Edward Kim | Equities.com |

We think opportunities abound in the sector.


Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins

Edward Kim | Equities.com |

The AstraZeneca deal continues to be a good one for Innate Pharma, year after year.


Cytovia Therapeutics To Go Public Via $600 Million SPAC Merger

Edward Kim | Equities.com |

The company will merge with Isleworth Healthcare Acquisition Corp.


WHO Endorses Pfizer's Oral COVID-19 Treatment Paxlovid for High-Risk Patients

Equities Staff | Equities.com |

Paxlovid may be the most potent COVID-19 therapy currently available.


Coeptis Therapeutics To Merge With SPAC, Uplist to Nasdaq

Edward Kim | Equities.com |

Coeptis is developing novel cell therapy platforms for cancer.


BioXcel Therapeutics Inks $260 Million Strategic Financing With Oaktree and Qatar Investment Authority

Edward Kim | Equities.com |

The financing will support the commercialization of BioXcel's recently approved Igalmi sublingual film for agitation associated with schizophrenia or bipolar I or II disorder.


Sponsored Financial Content

Market Movers